Does rimonabant pull its weight for type 2 diabetes?

Lancet

Volumn 368, Issue 9548, 2006, Pages 1632-1634

  Cleland, Stephen J ^a   Sattar, Naveed ^b  

^a STOBHILL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; PLACEBO; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ARTICLE; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; HUMAN; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; WEIGHT REDUCTION;

EID: 33846018374     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)69572-X     Document Type: Note

References (13)

1. Haslam D., Sattar N., and Lean M. ABC of obesity. Obesity-time to wake up. BMJ 333 (2006) 640-642
2. Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care 26 (2003) 2518-2523
3. Padwal R., Li S., and Lau D. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomised controlled trials. Int J Obes 27 (2003) 1437-1446
4. Padwal R., Kezouh A., and Etminan M. Long-term persistence with orlistat and sibutramine therapy in a population-based cohort. Obes Rev 7 suppl (2006) 46
5. Van Gaal L., Rissanen A., Scheen A., and for the RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
6. Pi-Sunyer F., Aronne L., Heshmati H., and for the RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. RIO-North America: a randomized controlled trial. JAMA 295 (2006) 761-775
7. Després J., Golay A., Sjöström L., and for the Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353 (2005) 2121-2134
8. Scheen A., Finer N., Hollander P., and for the RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet (2006). published online Oct 27, 2006. DOI:10.1016/S0140-6736(06)69571-8
9. Simons-Morton D., Obarzanek E., and Cutler J. Obesity research-limitations of methods, measurements, and medications. JAMA 295 (2006) 826-828
10. Curioni C., and Andre C. Rimonabant for overweight or obesity. Cochrane Database Syst Rev issue 4 (2006) CD006162
11. Arnone M., Maruani J., Chaperon F., et al. Selective inhibition of sucrose and alcohol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 132 (1997) 104-106
12. Lean M, Gruer L, Alberti KG, Sattar N. Obesity-can we turn the tide? BMJ (in press).
13. Tuthill A., Slawik H., O'Rahilly S., and Finer N. Psychiatric co-morbidities in patients attending specialist obesity services in the UK. QJM 99 (2006) 317-325